•  
  •  
  •  
  •  

2025-11-28 21:55:05

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi
  • Ms. Aditi Nayar, Chief Economist at ICRA Ltd On the Fiscal Deficit
  • Authum Investment & Infrastructure Ltd recommends 4:1 bonus issue
  • SBI Capital Markets Report on Q2FY26 GDP - From Capex to Consumption: How Policy Initiatives Sparked a GDP Beat
  • POSTURA: A Wall-Hung Closet Shaped for Comfort, Crafted for Everyday Life

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi
  • Amrutanjan Healthcare Re-launches Its Iconic Yellow Balm
  • Innoxel Lifesciences Successfully Completes EU GMP Inspection by Belgium's FAMHP
  • Lupin Foundation Earns CRISIL's Highest VO 1A Rating for Excellence in Social Responsibility
  • Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg
  • Glenmark Pharmaceuticals Receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility
  • SMS Pharmaceutical's associate company, VKT Pharma, receives US FDA approval for its reformulated Ranitidine
  • Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
  • Amrutanjan Healthcare Partners with Kaun Banega Crorepati to Celebrate 132 Years of Trust and Wellness
  • Mangalam Drugs and Organics Ltd receives repeat export order worth Rs. 15 crore
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Eris Lifesciences to consolidate its stake in Swiss Parenterals
  • Glenmark Pharmaceuticals announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD
  • Aptus Pharma Ltd enters into Urology therapy segment
  • GMP Inspection by Ministry of Health, Armenia at Alkem's manufacturing facility located at Sikkim, India
  • Shilpa Medicare Ltd receives 8 observations from USFDA for Unit 4 at Jadcherla
  • Syncom Formulations India Ltd acquires commercial property
  • Lupin Ltd receives 7 observations from USFDA for Goa manufacturing facility
  • NATCO Pharma Ltd receives 7 Observations from USFDA for API unit at Manali, Chennai
  • Ind-Swift Laboratories Ltd receives certifications from Bureau Veritas
  • Alkem launches probiotic 'DSS', the original De Simone formulation, in India for gut health management
  • Hester Biosciences Ltd appoints Mr. Ashish Desai as CFO and KMP
  • Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
  • SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi
  • Ms. Aditi Nayar, Chief Economist at ICRA Ltd On the Fiscal Deficit
  • Authum Investment & Infrastructure Ltd recommends 4:1 bonus issue
  • SBI Capital Markets Report on Q2FY26 GDP - From Capex to Consumption: How Policy Initiatives Sparked a GDP Beat
  • POSTURA: A Wall-Hung Closet Shaped for Comfort, Crafted for Everyday Life


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024